Announcements Trials
Browse Landscape

Phase

Phase NA 6Phase 2 6Phase 1/2 2Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 73Thoracic 17Breast 16Gynecologic 13Head & Neck 11Genitourinary 11Dermatologic 7Sarcoma 6CNS 5Endocrine 2NET 1Lymphoid 1

Conditions

Neuroendocrine Tumors 60Neoplasms 7Gastro-enteropancreatic neuroendocrine tumor 7Carcinoid Tumor 6Breast Neoplasms 6Pheochromocytoma 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Adenoma, Islet Cell 5Urinary Bladder Neoplasms 4Thyroid Neoplasms 4Paraganglioma 4Neoplasm Metastasis 4Lung Neoplasms 4Carcinoma, Neuroendocrine 4Carcinoma, Hepatocellular 4Brain Neoplasms 4Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Melanoma 3Carcinoma, Medullary 3Adrenocortical Carcinoma 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Testicular Neoplasms 2Sarcoma 2Neuroectodermal Tumors, Primitive 2Lymphoma 2Liver Neoplasms 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Gastrointestinal Neoplasms × NET × Clear all
NCT03411915 2022-05-10

DUET-1

Xencor, Inc.

Phase 1 Completed
62 enrolled
EndocrineGastrointestinalNET

Gastrointestinal Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡